|
Contents
|
|
|
|
Glioblastoma
|
|
|
|
|
Dresemann G, Weller M, Rosenthal MA, Wedding U,
Wagner W, Engel E, Heinrich B, Mayer-Steinacker R, Karup-Hansen A, Fluge O,
Nowak A, Mehdorn M, Schleyer E, Krex D, Olver IN, Steinbach JP, Hosius C,
Sieder C, Sorenson G, Parker R, Nikolova Z
Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to
standard dose temozolomide
J Neurooncol. 2009 Aug 18;. [Epub ahead of print]
.JPG)
Abstract
|
|
G. Dresemann
Imatinib (STI 571)/ plus hydroxyurea: Safety and efficacy in pre-treated,
progressive Glioblastoma Multiforme (GBM) patients (pts): An update on the
initial 30 pts
2005
ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1516.
Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005:
1516
|
|
G. Dresemann
Imatinib (STI571) plus hydroxyurea: Safety and
efficacy in pre-treated, progressive glioblastoma multiforme (GBM) patients
(pts)
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1550
|
|
G.
Dresemann
STI 571/hydroxyurea in progressive, pretreated
glioblastoma (GB) patients (pts.)
39th ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003. Abstract No.
465
|
|
|
Reardon
DA, Dresemann G, Taillibert S, Campone M, van den Bent M, Clement P,
Blomquist E, Gordower L, Schultz H, Raizer J, Hau P, Easaw J, Gil M, Tonn J,
Gijtenbeek A, Schlegel U, Bergstrom P, Green S, Weir A, Nikolova Z
Multicentre phase II studies evaluating imatinib plus hydroxyurea in
patients with progressive glioblastoma
Br J Cancer. 2009 Nov 10;. [Epub ahead of print]
Abstract
|
|
|
Glioma
(High-Grade)
|
|
|
|
H. S. Friedman, J.
Quinn, J. Rich, J. Vredenburgh, A.
Desjardins, S. Sathornsumetee, A. Salvado,
Z. Nikolova, D. Bigner and D. Reardon
Efficacy of imatinib mesylate plus hydroxyurea regimen in the treatment of
recurrent malignant glioma: Phase II study results
2005
ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1515.
Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005:
1515
|
|
|
Reardon DA, Egorin MJ, Desjardins A, Vredenburgh
JJ, Beumer JH, Lagattuta TF, Gururangan S, Herndon JE 2nd, Salvado AJ,
Friedman HS
Phase I pharmacokinetic study of the vascular endothelial growth factor
receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and
hydroxyurea for malignant glioma
Cancer. 2009 Feb 26;. [Epub ahead of print]
Abstract
|
|
|
Meningioma
|
|
|
|
Loven D, Hardoff R, Sever ZB, Steinmetz AP, Gornish M,
Rappaport ZH, Fenig E, Ram Z, Sulkes A
Non-resectable slow-growing meningiomas treated by
hydroxyurea
J Neurooncol. 2004 Mar-Apr;67(1-2):221-6.(Abstract+)
|
|
|
Newton HB.
Hydroxyurea chemotherapy in the treatment of meningiomas.
Neurosurg Focus.
2007 Oct;23(4):E11.
.png)
Full Text
| .png)
Reprint
|
|
Recurrent
Tumors
|
|
|
|
Chamberlain MC.
Hydroxyurea
for recurrent surgery and radiation refractory high-grade meningioma.
J Neurooncol.
2011 Nov 30. [Epub ahead of print]
Abstract |
.gif) Related articles
|
|
|
Chamberlain MC, Johnston SK.
Hydroxyurea
for recurrent surgery and radiation refractory meningioma: a retrospective
case series.
J Neurooncol.
2011 Feb 13. [Epub ahead of print]
Abstract |
Related articles
|
|
|
Reardon DA, Norden AD,
Desjardins A, Vredenburgh JJ, Herndon JE 2nd, Coan A, Sampson JH, Gururangan
S, Peters KB, McLendon RE, Norfleet JA, Lipp ES, Drappatz J, Wen PY,
Friedman HS.
Phase II study of Gleevec(®) plus hydroxyurea
(HU)
in adults with progressive or recurrent meningioma.
J Neurooncol. 2011
Sep 22. [Epub ahead of
print]
Abstract |
Related articles
|
|
|
|
